# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 2...